MAP2K7 and cardiac hypertrophy: MEK inhibitors have been used clinically as a therapeutic option for NS patients in different concentrations resulting in significant improvement in cardiac status and repression of cardiac hypertrophy in addition to normalization of pro-BNP levels in these patients26–28.